Inhibiting the renin-angiotensin system with ACE inhibitors or ARBs after MI

Current Heart Failure Reports

Volumn 4, Issue 4, 2007, Pages 190-197

  Palardy, Maryse ^b   Ducharme, Anique ^b   O'Meara, Eileen ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PERINDOPRIL; PLACEBO; PROSTACYCLIN; TRANDOLAPRIL; VALSARTAN;

CARDIOVASCULAR RISK; DIABETES MELLITUS; ECHOCARDIOGRAPHY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; NONHUMAN; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; MYOCARDIAL INFARCTION; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 38049185213     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-007-0012-7     Document Type: Review

References (67)

1. Pfeffer JM, Pfeffer MA, Braunwald E: Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. Circulation 1987, 75:1149-1155.
2. Pfeffer JM, Pfeffer MA, Fletcher PJ, et al.: Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol 1991, 260:H1406-H1414.
3. Pfeffer MA, Braunwald E: Ventricular enlargement following infarction is a modifiable process. Am J Cardiol 1991, 68:127D-131D.
4. Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327:669-677.
5. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993, 342:821-828.
6. Kober L, Torp-Pedersen C, Carlsen JE, et al.: A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995, 333:1670-1676.
7. Antman EM, Anbe DT, Armstrong PW, et al.: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004, 44:671-719.
8. Sharpe N, Murphy J, Smith H, et al.: Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet 1988, 1(8580):255-259.
9. Lax CJ, Domenighetti AA, Pavia JM, et al.: Transitory reduction in angiotensin AT2 receptor expression levels in postinfarct remodelling in rat myocardium. Clin Exp Pharmacol Physiol 2004, 31:512-517.
10. Schmieder R, Hilgers K, Schlaich MP, et al.: Renin-angiotensin system and cardiovascular risk. Lancet 2007, 369:1208-1219. Excellent and concise review of the pathophysiology of RAS in cardiovascular disease and of the newly discovered benefits of RAS inhibition.
11. Adachi Y, Saito Y, Kishimoto I, et al.: Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation 2003, 107:2406- 2408.
12. Yang Z, Bove CM, French BA, et al.: Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation 2002, 106:106-111.
13. Takai S, Jin D, Sakaguchi M, Miyazaki M: Chymase-dependent angiotensin II formation in human vascular tissue. Circulation 1999, 100:654-658.
14. Chrysant SG, Chrysant GS: The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens 2006, 8:261-268.
15. Cohn JN, Ferrari R, Sharpe N, et al.: Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000, 35:569-582.
16. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81:1161-1172.
17. St John Sutton M, Pfeffer MA, Plappert T, et al.: Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of Captopril. Circulation 1994, 89:68-75.
18. Pfeffer MA: Left ventricular remodeling after acute myocardial infarction. Annu Rev Med 1995, 46:455-466.
19. Savoye C, Equine O, Tricot O, et al.: Left ventricular remodeling after anterior wall myocardial infarction in modern clinical practice (from the REmodelage VEntriculaire [REVE] Study Group). Am J Cardiol 2006, 98:1144-1149.
20. Abdulla J, Barlera S, Latini R, et al.: A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur Heart J 2007, 9:129-135.
21. Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
22. Solomon SD, Skali H, Anavekar NS, et al.: Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation 2005, 111:3411-3419.
23. Flather MD, Yusuf S, Kober L, et al.: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355:1575-1581.
24. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987, 316:1429-1435.
25. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991, 325:293-302.
26. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992, 327:685-691.
27. Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
28. Swedberg K, Held P, Kjekshus J, et al.: Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992, 327:678-684.
29. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994, 343:1115-1122.
30. ISIS-4: a randomised factorial trial assessing early oral Captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995, 345:669-685.
31. Oral Captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chinese Cardiac Study (CCS-1) Collaborative Group. Chin Med J (Engl) 1997, 110:834-838.
32. Ambrosioni E, Borghi C, Magnani B: The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995, 332:80-85.
33. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998, 97:2202-2212.
34. Mielniczuk L, Stevenson LW: Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers in the management of congestive heart failure patients: what have we learned from recent clinical trials? Curr Opin Cardiol 2005, 20:250-255.
35. Yusuf S, Sleight P, Pogue J: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
36. Fox KM: Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003, 362:782-788.
37. Braunwald E, Amman EM, Beasley JW: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction - 2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002, 106:1893-1900.
38. Petrie MC, Padmanabhan N, McDonald JE, et al.: Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001, 37:1056-1061.
39. Mankad S, d'Amato TA, Reichek N, et al.: Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling. Circulation 2001, 103:2845-2850.
40. Yu CM, Tipoe GL, Wing-Hon LK, et al: Effects of combination of angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist on inflammatory cellular infiltration and myocardial interstitial fibrosis after acute myocardial infarction. J Am Coll Cardiol 2001, 38:1207-1215.
41. Konstam MA, Patten RD: Antagonism of the renin-angiotensin system in heart failure. In Heart Failure: A Companion to Braunwald's Heart Disease. Edited by Mann DJ. Philadelphia: Saunders; 2004:603-618.
42. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group: Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002, 360:752-760.
43. Cohn JN, Tognoni G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675.
44. McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767-771.
45. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
46. Matsubara H: Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998, 83:1182-1191.
47. Strauss MH, Hall AS: Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation 2006, 114:838-854. Interesting critical review discussing the underlying physiology and the available evidence on the possible relationship between ARB use and myocardial infarction.
48. Yamada T, Horiuchi M, Dzau VJ: Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A 1996, 93:156-160.
49. Kim MP, Zhou M, Wahl LM: Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol 2005, 78:195-201.
50. Teo K, Yusuf S, Sleight P, et al.: Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004, 148:52-61.
51. Domanski MJ, Exner DV, Borkowf CB, et al.: Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 1999, 33:598-604.
52. Solomon SD, Zelenkofske S, McMurray JJV, et al.: Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 2005, 352:2581-2588.
53. Mäkikallio TH, Barthel P, Schneider R, et al.: Frequency of sudden cardiac death among acute myocardial infarction survivors with optimized medical and revascularization therapy. Am J Cardiol 2006, 97:480-484.
54. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C: The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999, 20:748-754.
55. Pedersen OD, Bagger H, Kober L, et al.: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999, 100:376-380.
56. Patlolla V, Alsheikh-Ali AA, Al-Ahmad AM: The renin-angiotensin system: a therapeutic target in atrial fibrillation. Pacing Clin Electrophysiol 2006, 29:1006-1012.
57. Anavekar NS, McMurray JJV, Velazquez EJ, et al.: Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004, 351:1285-1295.
58. Tokmakova MP, Skali H, Kenchaiah S, et al.: Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study. Circulation 2004, 110:3667-3673.
59. Windt WAKM, Eijkelkamp WBA, Henning RH, et al.: Renal damage after myocardial infarction is prevented by renin-angiotensin-aldosterone system intervention. J Am Soc Nephrol 2006, 17:3059-3066.
60. Jose P, Tomson C, Skali H, et al.: Influence of proteinuria on cardiovascular risk and response to angiotensin-converting enzyme inhibition after myocardial infarction. J Am Coll Cardiol 2006, 47:1725-1727.
61. Aguilar D, Solomon SD, Kober L, et al.: Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004, 110:1572-1578.
62. Abdulla J, Pogue J, Abildstrom SZ, et al.: Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction - a meta-analysis. Eur J Heart Fail 2006, 8:90-96.
63. O'Meara E, Solomon S, McMurray J, et al.: Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2004, 25:1920-1926.
64. Gold LD, Krumholz HM. Gender differences in treatment of heart failure and acute myocardial infarction: a question of quality or epidemiology? Cardiol Rev 2006, 14:180-186.
65. White HD, Aylward PE, Huang Z, et al.: Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005, 112:3391-3399. Important data illustrating the underuse of recommended therapies in elderly post-MI patients in contemporary cardiovascular medicine. The discussion and recommendations of the authors are most pertinent to current clinical practice.
66. Ferrari R; Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators: Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) Study. Arch Intern Med 2006, 166:659-666.
67. Alexander KP, Newby LK, Armstrong PW, et al.: Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007, 115:2570-2589.